News | October 20, 2008

New Polymer-Free DES Technology Highlighted in JACC Intervention

October 21, 2008 - MIV Therapeutics Inc., a developer of coatings and drug-delivery systems for cardiovascular stents and implantable devices, said its technology was highlighted in the Oct. 21 issue of the Journal of the American College of Cardiology Intervention (JACC Intervention).

The peer-reviewed article, “Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment of Single De Novo Coronary Lesions - A First-In-Human Analysis of a Third Generation Drug-Eluting Stent (DES) System,” published preliminary results from the VESTASYNC I trial.

The article, authored by J. Ribamar Costa, Jr., M.D. et al, describes the positive results from the four-month follow-up of a multi-center, 15-patient, first-In-man study led by principal investigator Alexandre Abizaid, M.D., Ph.D., chief of coronary intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. The VESTAsync drug-eluting stent was successfully implanted in all cases, and there were no procedure and in-hospital complications. Life-long aspirin and five-month clopidogrel therapy were prescribed for all patients. At four months, in-stent late lumen loss was 0.30 0.25 mm and percent of stent obstruction was 2.8 2.2 percent. The VESTAsync drug-eluting stent late loss of 0.30 mm situates this new device among the highest-efficacy DES, with the advantage of a polymer-free system using less drug than first-generation equivalents. After up to six months of clinical follow-up, no major adverse cardiac event was registered.

At the Transcatheter Cardiovascular Therapeutics (TCT) conference in October 2007, Dr. Abizaid presented four-month follow-up efficacy data on 13 patients in the 15-patient study. The company has since reported excellent data at 12-months clinical follow up on all 15 patients.

MIV Therapeutics is currently in a pivotal trial for VESTAsync, the company’s polymer-free drug-eluting stent. The VESTASYNC II trial is a 120 randomized controlled study designed to demonstrate the safety and efficacy of the VESTAsync where patients are given anti-platelet medication (Plavix) for only three months. The current anti-platelet standard is a minimum duration of one year and in many cases is life-long therapy.

For more information:,

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init